ASSESSMENT OF EFFECTIVENESS OF ANTI-RECURRENT AND HORMONAL THERAPY IN WOMEN WITH UTERINE FIBROIDS IN PREGRAVIDAL PREPARATION

Aim. This study was designed to evaluate the effectiveness of sequential prescription of drugs for anti-recurrent therapy of the uterine fibroids (UF) and combined oral contraceptives (COC) in pregravidal preparation.

Materials and methods. There was conducted a prospective, nonrandomized and controlled cohort study of 150 women with UF  who are planning a pregnancy after the organ-preserving treatment  of uterine fibroids by means of myomectomy with laparoscopic  access and pregravidal preparation. The immunohistochemical (IHC)  study of the intensity expression of Ki 67, p53, Bcl-2 was performed  for the differential diagnosis of reactive proliferation from dysplasia  in the distant fibroid node and the selection of anti-recurrent therapy.

Results. The duration of the UF disease does not depend on the intensity of expression of p53, Ki-67 or Bcl-2, the level of expression  of the progesterone receptors in the distant fibroid node. A negative average correlation between the level of hemoglobin  before myomectomy, the duration of the disease (r = -0.3867) and  the number of nodes (r = -0.5389) was revealed. After the end of  the anti-recurrent treatment in women who underwent organ- preserving treatment of uterine fibroids, the prescription of COC is connected with a further decrease in the size of fibroid nodes remaining after myomectomy from 15.81±0.22 mm to 8.94±0.45  mm (p<0.05), the number of fibroid nodes from 2.25±0.08 to  0.91±0.06 (р<0.05).

Conclusion. The combination of anti-recurrent therapy with the subsequent prescription of the COC for prevention of the UF growth  in women planning a pregnancy after myomectomy with endoscopic  access is highly effective.

1. Younas K., Hadoura E., Majoko F. et al. A review of evidence-based management of uterine fibroids. Obstetrician Gynaecologist. 2016; 18: 3-42. [Younas K., Hadoura E., Majoko F. et al. A review of evidence-based management of uterine fibroids. Obstetrician Gynaecologist. 2016; 18: 3-42].

2. Радзинский В.Е., Князев С.А., Костин И.Н. Акушерский риск. Максимум информации – минимум опасности для матери и младенца. Москва: Эксмо, 2009. 288 с. [Radzinskij V.E., Knyazev S.A., Kostin I.N. Akusherskij risk. Maksimum informacii – minimum opasnosti dlya materi i mladenca. Moscow: Ehksmo; 2009. 288 р. (in Russ.)]

3. Eltoukhi H.M., Modi M.N., Weston M. et al. The health disparities of uterine fibroid tumors for African American women: a public health issue. American Journal of Obstetrics & Gynecology. 2014; 210(3): 194-199. DOI: 10.1016/j.ajog.2013.08.008.

4. Gunnala V., Pereira N., Irani M. et al. Novel Fumarate Hydratase Mutation in Siblings With Early Onset Uterine Leiomyomas and Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome. Int J. Gynecol Pathol. 2018 May; 37(3): 256-261. DOI: 10.1097/PGP.0000000000000423.

5. Trofimova T., Lizneva D., Suturina L.et al. Genetic basis of eugonadal and hypogonadal female reproductive disorders. Best Pract Res Clin Obstet Gynaecol. 2017 Oct; 44: 3-14. DOI: 10.1016/j.bpobgyn.2017.05.003.

6. Awowole I.O., Makinde O.N., Badejoko O.O. et al. Clinical correlates of leiomyoma estrogen and progesterone receptors among Nigerian women. Int J Gynaecol Obstet. 2016; 135(3): 314- 318. DOI: 10.1016/j.ijgo.2016.06.019.

7. Башмакова Н.В., Рощина М.О., Чистяков М.А. Оценка гистологических и иммуногистохимических изменений в эндометрии после проведения эмболизации маточных артерий по поводу миомы матки. Акушерство и гинекология. 2012; 8-1: 20- 24. [Bashmakova N.V., Roshchina M.O., Chistyakov M.A. Evaluation of the histological and immunohistochemical changes in the endometrium after uterine artery embolization for uterine myoma. Obstetrics and gynecology. 2012; 8-1: 20-24. (In Russ., English abstract)].

8. Сафарова С.М. Морфологическая характеристика миомы матки среди женщин репродуктивного возраста. Журнал акушерства и женских болезней. 2017; 1: 27-31. [Safarova S.M. Morphological characteristics of uterine fibroids among women of reproductive age. Journal of Obstetrics and Women's Diseases. 2017; 1: 27-31. (In Russ., English abstract)].